ADAMTS4 and autoimmune polyendocrinopathy: A dose-effect was observed with ACS and APS treatment, with 50% v/v treatment producing greater effect on the expression of TNF-α, ADAMTS-4, COL2A1 and ACAN vs. 25% v/v (Figure 5).